Please assess the completion status of the following clinical trial:

Trial Title: Iloperidone in Mixed States of Bipolar Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female;~2. Age 18 years and older~3. Patients on:~   * Li at a stable dose for 2 weeks or longer, and a serum level at screening of greater than or equal to 0.5 mEq/l OR~  * DIV dose for 2 weeks or longer, and a serum level at screening of greater than or equal to 45 ug/ml OR~  * LAM (dosage/day ≥100mg) at a stable dose for 2 weeks or longer OR~  * Any combination 3a, 3b, or 3c~4. Patients meeting DSM-IV TR diagnosis of bipolar disorder, I or II, as assessed using the MINI, (Sheehan et al., 1998) PLUS any ONE of criteria 5 or 6 or 7~5. Patients meeting DSM-IV TR diagnostic criteria for a mixed manic episode with Young Mania Rating Scale (YMRS) score\>/=14 and Montgomery Asberg Depression Rating Scale (MADRS) score\>/=14~6. Patients meeting the criteria for a manic/hypomanic episode for at least 2 days with the simultaneous presence of Young Mania Rating Scale (YMRS) score\>/=14 PLUS Montgomery Asberg Depression Rating Scale (MADRS) score\>/=14 ;~7. Patients meeting DSM-IV TR diagnostic criteria for a major depressive episode with the simultaneous presence of MADRS score\>/=14 PLUS meeting the criteria for a manic/hypomanic episode for at least 2 days with the simultaneous presence of Young Mania Rating Scale (YMRS) score\>/=14~Exclusion Criteria:~1. Patients with a current Axis I diagnosis of schizophrenia, schizophreniform disorder, schizotypal disorder, bipolar disorder with psychotic sub-type that requires hospitalization, drug induced mania or AIDS induced mania~2. Women with a positive pregnancy test or who are lactating~3. Women of child-bearing potential who are not practicing a clinically accepted method of contraception~4. Patients with general medical conditions that contraindicate psychoactive medications or uncontrolled medical disorder or central nervous system diseases.~5. Patients whose clinical status requires inpatient or day hospital treatment~6. History of severe side effects associated with therapeutic doses of Li, DIV, LAM~7. Alcohol or drug dependent at time of enrollment~8. Suicidal at time of enrollment.~9. Current or previous exposure to iloperidone~10. Patients taking medication that cause QTC prolongation~11. Patients with serious cardiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label iloperidone (Type: EXPERIMENTAL): open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.

Based on this trial design, predict the completion outcome and termination type (if applicable).